CoChat
Sign Up
Cited by 67

Loss of microRNA-205 expression is associated with melanoma progression

Liu, Shujing, Tetzlaff, Michael T, Liu, Aihua, Liegl-Atzwanger, Bernadette, Guo, Jun, Xu, Xiaowei·2012·Laboratory Investigation
DOI 10.1038/labinvest.2012.62
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/labinvest.2012.62

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miR-205-5p is highly expressed in melanocytes and downregulated in melanoma, and is inversely correlated with melanoma progression (21).

    “MiR-205–5p that is highly expressed in melanocytes and downregulated in melanoma is inverse correlated with melanoma progression (21).”

    From Distribution of miRNA expression across human tissues (2016) · cites this paper as [21]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 54

  1. Altekruse SFK, Krapcho MCL. SEER Cancer Statistics Review, 1975-2007.
  2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
  3. Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 2010;60:301-316.
  4. Berezikov E, Guryev V, van de Belt J, et al. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005; 120:21-24.
  5. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
  6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
  7. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866.
  8. Liu X, Fortin K, Mourelatos Z. MicroRNAs: biogenesis and molecular functions. Brain Pathol 2008;18:113-121.
  9. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120:1046-1054.
  10. Cortez MA, Ivan C, Zhou P, et al. microRNAs in cancer: from bench to bedside. Adv Cancer Res 2010;108:113-157.
  11. Fabbri M, Calin GA. Epigenetics and miRNAs in human cancer. Adv Genet 2010;70:87-99.
  12. Ferdin J, Kunej T, Calin GA. Non-coding RNAs: identification of cancer- associated microRNAs by gene profiling. Technol Cancer Res Treat 2010;9:123-138.
  13. Le XF, Merchant O, Bast RC, et al. The roles of microRNAs in the cancer invasion-metastasis cascade. Cancer Microenviron 2011;3:137-147.
  14. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-838.
  15. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008;26:462-469.
  16. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-2261.
  17. Liu A, Tetzlaff MT, Vanbelle P, et al. MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin- embedded tissues. Int J Clin Exp Pathol 2009;2:519-527. miR-205 inhibits melanoma cell migration S Liu et al 18. Caramuta S, Egyhazi S, Rodolfo M, et al. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 2010;130:2062-2070.
  18. Chen J, Feilotter HE, Pare GC, et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 2010;176:2520-2529.
  19. Jukic DM, Rao UN, Kelly L, et al. Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med 2010;8:27.
  20. Philippidou D, Schmitt M, Moser D, et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res 2010;70:4163-4173.
  21. Satzger I, Mattern A, Kuettler U, et al. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer 2009;126:2553-2562.
  22. Schultz J, Lorenz P, Gross G, et al. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 2008;18:549-557.
  23. Segura MF, Belitskaya-Levy I, Rose AE, et al. Melanoma microRNA signature predicts post-recurrence survival. Clin Cancer Res 2010;16: 1577-1586.
  24. Worley LA, Long MD, Onken MD, et al. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res 2008;18:184-190.
  25. Dar AA, Majid S, de Semir D, et al. miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem 2011;286:16606-16614.
  26. Nelson PT, Baldwin DA, Kloosterman WP, et al. RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA 2006;12:187-191.
  27. Nelson PT, Baldwin DA, Scearce LM, et al. Microarray-based, high- throughput gene expression profiling of microRNAs. Nat Methods 2004;1:155-161.
  28. Tetzlaff MT, Liu A, Xu X, et al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol 2007;18:163-173.
  29. Liu A, Xu X. MicroRNA isolation from formalin-fixed, paraffin- embedded tissues. Methods Mol Biol 2011;724:259-267.
  30. Kumar SM, Yu H, Edwards R, et al. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res 2007;67:3177-3184.
  31. Liu S, Yu M, He Y, et al. Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology 2008;47:1964-1973.
  32. Xu Z, Maroney AC, Dobrzanski P, et al. The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Mol Cell Biol 2001;21:4713-4724.
  33. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR- 205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601.
  34. Matsushima K, Isomoto H, Yamaguchi N, et al. MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med 2011;9:30.
  35. Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009;138: 592-603.
  36. Dykxhoorn DM. MicroRNAs and metastasis: little RNAs go a long way. Cancer Res 2010;70:6401-6406.
  37. Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22:894-907.
  38. Hsu MY, Meier FE, Nesbit M, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down- regulates expression of invasion-related adhesion receptors. Am J Pathol 2000;156:1515-1525.
  39. Tucci MG, Lucarini G, Brancorsini D, et al. Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Br J Dermatol 2007;157:1212-1216.
  40. Hsu MY, Wheelock MJ, Johnson KR, et al. Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc 1996;1:188-194.
  41. Gottardo F, Liu CG, Ferracin M, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007;25:387-392.
  42. Wiklund ED, Bramsen JB, Hulf T, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2010;128:1327-1334.
  43. Wang X, Tang S, Le SY, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008;3:e2557.
  44. Wu W, Lin Z, Zhuang Z, et al. Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev 2009;18:50-55.
  45. Hiroki E, Akahira J, Suzuki F, et al. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 2009; 101:241-249.
  46. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67:8699-8707.
  47. Radojicic J, Zaravinos A, Vrekoussis T, et al. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011;10:507-517.
  48. Sempere LF, Christensen M, Silahtaroglu A, et al. Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007;67:11612-11620.
  49. Gandellini P, Folini M, Longoni N, et al. miR-205 exerts tumor- suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009;69:2287-2295.
  50. Majid S, Dar AA, Saini S, et al. MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 2010;116:5637-5649.
  51. Majid S, Saini S, Dar AA, et al. MicroRNA-205 inhibits Src- mediated oncogenic pathways in renal cancer. Cancer Res 2011;71: 2611-2621.
  52. Childs G, Fazzari M, Kung G, et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 2009;174:736-745.
  53. Schinke C, Mo Y, Yu Y, et al. Aberrant DNA methylation in malignant melanoma. Melanoma Res 2010;20:253-265.
  54. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-2147.

Cited by

Sorted by citations

Authors
Liu, S., Tetzlaff, M. T., Liu, A., Liegl-Atzwanger, B., Guo, J., & Xu, X.
Venue
Laboratory Investigation
Publisher
Elsevier BV
Published
2012-07
Volume
92
Issue
7
Pages
1084-1096
ISSN
0023-6837
DOI
10.1038/labinvest.2012.62
Cited by
67
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review